Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR +0.35%67 Cash Ratio is 1.97 as of Mar. 2026, which is 328% above its 10-year median of 0.46. GuruFocus rates NGM:MCLR with a GF Score™ of 67/100 and a GF Value™ of kr2.37 (Modestly Overvalued). Among 840 Medical Devices & Instruments companies, Medclair AB ranks better than 67.38% on this metric.
Medclair AB has a Cash Ratio of 1.97. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Medclair AB's Cash Ratio or its related term are showing as below:
NGM:MCLR'
s Cash Ratio Range Over the Past 10 Years
Min: 0.12 Med: 0.46 Max: 5.1
Current: 1.97
During the past 11 years, Medclair AB's highest Cash Ratio was 5.10. The lowest was 0.12. And the median was 0.46.
NGM:MCLR's Cash Ratio is ranked better than 67.38% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 0.975
vs NGM:MCLR: 1.97
Medclair AB (NGM:MCLR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Medclair AB Cash Ratio Related Terms
Medclair AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Medclair AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medclair AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Medclair AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a Cash Ratio of 1.97 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Medclair AB and its competitors. This is 328% above median its historical median of 0.46. Over the past decade, Medclair AB's Cash Ratio has ranged from 0.12 to 5.10. According to the industry distribution chart, Medclair AB ranks #274 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 32.6%.
Is Medclair AB's Cash Ratio too high?
Medclair AB's current Cash Ratio of 1.97 is 328% above median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 5.10. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Medclair AB's value of 1.97 is 102.1% above this industry median. Based on the distribution chart, Medclair AB ranks #274 out of 840 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medclair AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #274 out of 840 companies for Cash Ratio. This puts Medclair AB in the upper half of its industry. The industry median Cash Ratio is 0.98. Medclair AB's value of 1.97 is 102.1% above this benchmark. Historically, Medclair AB's own Cash Ratio has ranged from 0.12 to 5.10 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.98, Medclair AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current Cash Ratio of 1.97 is 102.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current Cash Ratio is 1.97, which is 328% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.37, compared to a current price of kr2.89 — trading 21.9% above its estimated fair value. The current Cash Ratio is 1.97, which is 328% above median its 10-year median of 0.46 and 102.1% above the Medical Devices & Instruments industry median of 0.98. Medclair AB's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Cash Ratio is 1.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.89 is trading 21.9% above its estimated GF Value™ of kr2.37.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
Cash Ratio: 1.97 (328% above median its 10-year median of 0.46)
GF Value™: kr2.37 vs. price of kr2.89 (21.9% above fair value)
Industry Position: 102.1% above the Medical Devices & Instruments median (#274 of 840)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
67GF Score
Get the complete analysis for NGM:MCLR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
